Mercapton (Dimercaptosuccinic Acid)

Dimercaptosuccinic acid acts as a bidentate chelator that binds divalent metal ions such as Pb²⁺, Hg²⁺, Cd²⁺ and As³⁺. The resulting complexes are highly water‑soluble and non‑toxic, allowing the kidneys to excrete them in the urine, thereby lowering the total body load of the toxic metal.

The exact dose and infusion rate of Mercapton are determined by the prescribing clinician based on the patient’s weight, severity of metal exposure, renal function and laboratory monitoring. Dosing regimens are individualized and should follow the latest clinical guidelines or the product’s prescribing information.

Safety data for dimercaptosuccinic acid in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Mercapton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The primary alternative chelator for heavy‑metal poisoning is calcium disodium edetate (CaEDTA). Compared with CaEDTA, dimercaptosuccinic acid (Mercapton) has a higher affinity for mercury and can be administered intravenously for rapid effect, while CaEDTA is often used for lead and is available in both oral and parenteral forms. Choice depends on the specific metal and clinical scenario.

Mercapton should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended storage period.

Mercapton is given by intravenous infusion under medical supervision. The solution is diluted in an appropriate compatible IV fluid and infused over a prescribed period, typically ranging from 30 minutes to several hours, depending on the clinical protocol and patient tolerance.

The most serious adverse events include acute renal failure, anaphylactic reactions and severe hepatotoxicity. Patients should be closely monitored for sudden changes in kidney function, signs of allergic response such as rash or breathing difficulty, and abnormal liver enzymes during treatment.

Mercapton is contraindicated in patients with known hypersensitivity to dimercaptosuccinic acid or any component of the formulation. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or those receiving other nephrotoxic agents, unless the treating physician determines that benefits outweigh the risks.